Last reviewed · How we verify

Pregabalin & Magnesium sulphate

National Cancer Institute, Egypt · Phase 3 active Small molecule

Pregabalin & Magnesium sulphate is a Anticonvulsant/analgesic combination Small molecule drug developed by National Cancer Institute, Egypt. It is currently in Phase 3 development for Chemotherapy-induced peripheral neuropathy (CIPN), Cancer-related neuropathic pain.

Pregabalin reduces neuronal calcium influx and neurotransmitter release while magnesium sulphate acts as an NMDA receptor antagonist, together modulating neuropathic pain and potentially chemotherapy-induced peripheral neuropathy.

Pregabalin reduces neuronal calcium influx and neurotransmitter release while magnesium sulphate acts as an NMDA receptor antagonist, together modulating neuropathic pain and potentially chemotherapy-induced peripheral neuropathy. Used for Chemotherapy-induced peripheral neuropathy (CIPN), Cancer-related neuropathic pain.

At a glance

Generic namePregabalin & Magnesium sulphate
SponsorNational Cancer Institute, Egypt
Drug classAnticonvulsant/analgesic combination
TargetAlpha-2-delta calcium channel subunit; NMDA receptor
ModalitySmall molecule
Therapeutic areaOncology; Neurology
PhasePhase 3

Mechanism of action

Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels, decreasing excitatory neurotransmitter release in the central and peripheral nervous systems. Magnesium sulphate blocks NMDA receptors and modulates calcium homeostasis. This combination is hypothesized to provide synergistic neuroprotection and pain relief, particularly in cancer-related neuropathic conditions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Pregabalin & Magnesium sulphate

What is Pregabalin & Magnesium sulphate?

Pregabalin & Magnesium sulphate is a Anticonvulsant/analgesic combination drug developed by National Cancer Institute, Egypt, indicated for Chemotherapy-induced peripheral neuropathy (CIPN), Cancer-related neuropathic pain.

How does Pregabalin & Magnesium sulphate work?

Pregabalin reduces neuronal calcium influx and neurotransmitter release while magnesium sulphate acts as an NMDA receptor antagonist, together modulating neuropathic pain and potentially chemotherapy-induced peripheral neuropathy.

What is Pregabalin & Magnesium sulphate used for?

Pregabalin & Magnesium sulphate is indicated for Chemotherapy-induced peripheral neuropathy (CIPN), Cancer-related neuropathic pain.

Who makes Pregabalin & Magnesium sulphate?

Pregabalin & Magnesium sulphate is developed by National Cancer Institute, Egypt (see full National Cancer Institute, Egypt pipeline at /company/national-cancer-institute-egypt).

What drug class is Pregabalin & Magnesium sulphate in?

Pregabalin & Magnesium sulphate belongs to the Anticonvulsant/analgesic combination class. See all Anticonvulsant/analgesic combination drugs at /class/anticonvulsant-analgesic-combination.

What development phase is Pregabalin & Magnesium sulphate in?

Pregabalin & Magnesium sulphate is in Phase 3.

What are the side effects of Pregabalin & Magnesium sulphate?

Common side effects of Pregabalin & Magnesium sulphate include Dizziness, Somnolence, Peripheral edema, Hypermagnesemia (with magnesium sulphate).

What does Pregabalin & Magnesium sulphate target?

Pregabalin & Magnesium sulphate targets Alpha-2-delta calcium channel subunit; NMDA receptor and is a Anticonvulsant/analgesic combination.

Related